ConceptioArchiveCode of Federal Regulations (eCFR)
Code of Federal Regulations (eCFR)public full text

21 CFR Part 348 — External Analgesic Drug Products for Over-the-Counter Human Use

Office of the Federal Register (NARA) · Code of Federal Regulations (eCFR, Office of the Federal Register)
Code of Federal Regulations (eCFR) · Legal · License: Public Domain
Open Source ↗
departmentofhealthandhumanservicesfoodfoodanddrugadministration
united states, us regulation, us federal regulation, code of federal regulations, cfr, federal regulation, 21, 348, part 348, 21 cfr 348, 21 cfr part 348, food, and, drugs, food and drug administration, department of health and human services, drugs for human use

PART 348—EXTERNAL ANALGESIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371. Source: 57 FR 27656, June 19, 1992, unless otherwise noted. Subpart A—General Provisions § 348.1 Scope. (a) An over-the-counter external analgesic drug product in a form suitable for topical administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this part and each general condition established in § 330.1 of this chapter. (b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted. § 348.3 Definitions. As used in this part: (a) Male genital desensitizing drug product. (b) [Reserved] Subpart B—Active Ingredients § 348.10 Analgesic, anesthetic, and antipruritic active ingredients. The active ingredient of the product consists of any of the following within the specified concentration established for each ingredient: (a) Male genital desensitizers. (2) Lidocaine in a metered spray with approximately 10 milligrams per spray. (b) [Reserved] Subpart C—Labeling § 348.50 Labeling of external analgesic drug products. (a) Statement of identity. (1) For products containing any ingredient identified in § 348.10(a). (2) [Reserved] (b) Indications. (1) For products containing any ingredient identified in § 348.10(a). (ii) “For temporary male genital desensitization, helping to slow the onset of ejaculation.” (iii) “Helps in temporarily” (select one of the following: “retarding the onset of,” “slowing the onset of,” or “prolonging the time until”) followed by “ejaculation.” (iv) “For reducing oversensitivity in the male in advance of intercourse.” (2) [Reserved] (c) Warnings. (1) For products containing any ingredient identified in § 348.10(a). (ii) “Avoid contact with the eyes.” (iii) “If you or your partner develop a rash or irritation, such as burning or itching, discontinue use. If symptoms persist, consult a doctor.” (2) [Reserved] (d) Directions. (1) For products containing any ingredient identified in § 348.10(a) For products containing benzocaine identified in § 348.10(a)(1). (ii) For products containing lidocaine identified in § 348.10(a)(2). (2) [Reserved] (e) The word “physician” may be substituted for the word “doctor” in any of the labeling statements in this section.

Related documents

Record · ID 506834 · SHA-256 6363bf129e91d096
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.